FILING ANALYSIS · MONDAY, NOVEMBER 9
TG THERAPEUTICS, INC. TGTX — 8-K: Results of Operations and Financial Condition
positive
TG Therapeutics raises full-year 2026 total global revenue guidance to approximately $1 billion and full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915-920 million, driven by solid third-quarter performance and a strong anticipated fourth quarter, with the company highlighting continued momentum in its IV business and potential to expand the BRIUMVI franchise through new
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →